Drug intelligence / Profile preview

glibenclamide + metformin

Development stage
Approved
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

Glibenclamide + metformin is a fixed-dose combination oral anti-diabetic medication used to treat type 2 diabetes. It combines two agents with complementary mechanisms of action. Glibenclamide (also known as glyburide) is a sulfonylurea that stimulates insulin release from pancreatic beta cells, thereby lowering blood glucose levels. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. This combination helps improve glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient[1][3][4][5].

Brand names
GlucovanceGlucored ForteGlibmit M
Other names
glyburide/metforminglibenclamide/metformin hydrochloride
02

Targets

GPD2 (Glycerol-3-phosphate dehydrogenase 2)ND1 (Mitochondrial electron transport chain complex I)SUR1 (Sulfonylurea receptor 1)KCNJ11 (Atp-sensitive inward rectifier potassium channel 11)

Beyond the preview

Go deeper on glibenclamide + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on glibenclamide + metformin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call